BioCurity Pharmaceuticals Inc.

Because fighting cancer is hard enough!

BioCurity Pharmaceuticals Inc.

Because fighting cancer is hard enough!

Jupiter, FL
BioCurity is a clinical stage biopharmaceutical company with a mission to materially improve and transform radiation therapy for cancer patients. Our proprietary technology is designed to prevent or mitigate damage to skin and normal internal tissue during radiation therapy without impairing the effectiveness of the radiation treatment on the patient’s cancer cells. The proposed drugs generated from BioCurity’s proprietary technology have been preclinically tested for multiple cancers including breast, lung, head and neck, prostate and colorectal cancer. The delivery system of the proposed drug includes a topical for the skin to prevent or mitigate skin damage (radiation dermatitis) and an intravenous (IV) formulation for internal tissue protection from radiation damage.


Days Left
Price per Share
Offering Type
Min. Investment


Days Left
Price per Share
Offering Type
Min. Investment

Bonus Rewards

Get rewarded for investing more into BioCurity Pharmaceuticals Inc.

StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Reasons to Invest

Our technology has the potential to exponentially transform the radiation experience for cancer patients with a drug to prevent burns, blistering, permanent scarring and damage
Seven issued US patents with fully paid license for its technology in the US and International patents pending
Our team of experts brings over two decades of cancer treatment research, global biotechnology distribution and corporate governance

"Because we believe that fighting cancer is hard enough"

Radiation therapy is a common cancer treatment that can have serious side effects

Most everyone has a friend or family member who has endured the sometimes painful, permanent or serious side effects from radiation therapy that is prescribed by their physicians for their cancer treatment regimen.

Clinical development consultants and radiation oncologists agree that if effective, cancer patients would want a drug designed to protect their skin and internal tissue from radiation damage. Our preclinical proof of concept studies in animals was conducted at an MD Anderson Cancer Center affiliate and in collaboration with highly regarded research organizations. BioCurity is looking to move forward in developing its proposed drugs and positively impacting the cancer treatment process for millions of patients worldwide.

There is an unmet patient need to prevent or mitigate the side effects of life-saving radiation therapy

Globally, approximately 6 million newly diagnosed patients with cancer receive radiation therapy annually. Some of the adverse side effects of this treatment include skin burns, blistering, permanent scarring, and damage to internal non-cancer healthy tissue. Peer-reviewed articles describe reported cases of short term and long term side effects sustained by cancer patients who have received radiation therapy as part of their cancer treatment.

Complications of radiation therapy in different types of cancers:

  • Breast - Scarring of breasts, blisters, scars, pain
  • Head and Neck - Drying of mouth (loss of saliva), difficulty swallowing and other symptoms (xerostomia), skin burning, pan
  • Prostate - Inflammation of rectum, damage to urinary bladder (frequent painful urination), skin burning, pain
  • Colorectal - Damage to bowel (bleeding of rectum), skin burning, pain
  • Lung - Scarring of the lungs (pneumonia), skin burning, pain

The lack of adequate treatment options available to prevent or mitigate the damage to normal tissue causes an unmet global need. Beyond that, there are currently no products on the market to prevent radiation dermatitis for cancer patients.

First-of-its-kind drug to prevent or mitigate damage to normal tissue during radiation

As demonstrated in preclinical studies, BioCurity’s technology is designed to protect healthy skin and internal organs without getting in the way of radiation therapy targeting cancer cells. This radiation exposure creates free radicals (also known as Reactive Oxygen Species) that damage cell DNA and cause cell death in cancerous and normal cells.

Eliminating Free radicals

BioCurity’s proprietary technology is intended to eliminate these free radicals, protecting the normal skin and internal tissues from unwanted DNA damage and the ensuing side effects-- without interfering with the treatment of cancer cells. Our first proposed drug BC 101 is a topical for radiation dermatitis and with the support from a biotech venture or as part of a joint venture with a pharma company, we believe our proposed IV drug (for internal tissue damage) could be developed as well.

Source, Source, Source, Source, Source, Source

Every patient undergoing radiation therapy for cancer treatment is a potential customer

Globally, approximately 6 million out of the approximate 18 million newly diagnosed cancer patients receive radiation therapy annually and 1 million of them live in the United States. BioCurity’s technology and drug candidates have the potential to significantly reduce radiation toxicity not just for these newly diagnosed patients but also for the many other patients who receive radiation as part of their ongoing treatment for cancer.

The first target market we intend to test with our BC 101 is breast cancer patients. It is expected to provide a material decrease in government and insurance funds required to treat skin damage of burns, scars, and blisters:

  • Breast cancer is leading cancer in the United States for women, and it is estimated that 1 in 8 women in the United States will develop breast cancer over their lifetime.
  • Radiation treatment for breast cancer can be used after lumpectomy, after mastectomy, for pain management, for managing metastatic breast cancer and for treating locally advanced breast cancer
  • Some form of skin damage has been referenced in the scientific literature to inflict nearly all women with breast cancer who are receiving radiation therapy.
  • The short term and long term skin damage associated with radiation therapy for breast cancer patients include localized burning and blisters that can often be permanent, open wounds, extreme swelling and tenderness of the breast and surrounding lymph nodes, and permanent scars.

Preclinical trials  completed and third-party experts see promise

BioCurity has presented its preclinical data and technology to the Chief of Medicine
 and Chairman of the Radiation Oncology Department at leading United States cancer centers and received notable interest in its proposed topical and IV drugs.

After meeting with the FDA in a Pre-Investigational New Drug Application (Pre-IND) meeting, BioCurity has a path of development for its BC 101 for breast cancer. Upon adequate funding, management is ready to 
execute its plan as the path set out by the FDA. 

Increasing the attractiveness to capital markets

With a fully paid, license for its technology that is freely transferable, BioCurity is well situated for collaborative transactions with pharmaceutical strategic groups. Favorable exit strategies for biotech companies include proceeding with clinical development up through a demonstration of clinical efficacy and then licensing the product or soliciting an acquisition. 

Management has made efforts to structure the company with multiple exit strategies along the path of growth, to enable it to consider opportunities at any point along its growth curve.

Striving to be the first FDA approved drug for the prevention of radiation dermatitis 

Despite recent advancements in technology for new treatments, there is no definitive intervention for the prevention of skin damage.

As such, if approved, BioCurity’s first proposed topical drug, BC 101 would be the first and only FDA approved drug for the prevention of radiation dermatitis in patients receiving radiation treatment for cancer. The lack of effective prevention and a large number of potential cancer patients represents a significant and global unmet need and tremendous value proposition for BC 101 and other potential drugs such as the IV formulation for the protection of internal tissues.  

Reaching all cancer patients going through radiation therapy

Over the next three years, given adequate funding, we will be working to clinically develop our topical product for breast cancer patients. We intend to build out a management team, bring in house consultants from the drug industry and submit the New Drug Application for breast cancer product.

While our immediate focus is developing a new investigational topical product for breast cancer radiation therapy, we have greater aspirations. With the establishment of efficacy for breast cancer then additional clinical trials with our topical product for other cancers could begin. Eventually, with a joint venture with a pharma company or support from a biotech venture fund, we aim to develop an IV formulation of our product designed to protect the internal tissue from radiation.

A strong management team and roster of advisors

BioCurity has built a world-class team, balancing decades of experience in science, business operations, international, and legal/banking experience.

Dr. Cheryl Baker Ph.D., the scientific founder, performed the preclinical development and testing alongside radiation oncologists, medical oncologists, and others in the medical community. She has published more than 45 peer-reviewed manuscripts, book chapters, and articles. Chairman of the Board, Sam Merchant, brings expertise in structuring and negotiating transactions globally in Biotechnology, Pharmaceutical R&D in the production, manufacturing, and distribution of products provides value-added for BioCurity’s overall clinical development goals. Executive board member Nancy Cass, Esq, uses her depth of knowledge in transactional and securities law to make certain BioCurity is transaction-ready and the due diligence and corporate governance is properly performed and managed. BioCurity is also guided by a group of expert third-party advisors with substantial experience in all phases of drug development and the biotech industry - they are our very dedicated Consultants and Advisors - MDs, PhDs, MBAs, with decades of Biotech experience.

Join us in transforming radiation therapy for cancer patients

All investments to date have been to friends and family without general outside marketing. BioCurity is ready to share its story and to reach those non-accredited investors who have been barred from participating in past raises. With adequate funding, we can continue to develop BioCurity technology and meet the high demand for a product that can transform the radiation therapy experience by limiting side effects.

Offering Summary



BioCurity Pharmaceuticals Inc.

Corporate Address


110 Front Street, Suite 300, Jupiter, FL 33477

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


CF Convertible Preferred Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below

The 10% Bonus for StartEngine Shareholders

BioCurity Pharmaceuticals Inc. will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of CF Convertible Preferred Stock at $4.25 / share, you will receive 110 CF Convertible Preferred Stock shares, meaning you'll own 110 shares for $425. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Vendor payments. Any expense labeled “Travel and Entertainment”.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$342,484.00 USD
$409,874.00 USD
Cash And Cash Equivalents
$167,281.00 USD
$203,307.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$2,121,930.00 USD
$1,320,617.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$2,059,818.00 USD
-$2,844,968.00 USD


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


BioCurity Pharmaceuticals - About Us

2 days ago

Palm Beach County Business Development Board-BioCurity Joint Press Release

10 days ago










January 2, 2020 – Jupiter, FL – Tucked away at Harbourside Place in Jupiter is a company with patented technologies, primed to substantially improve the quality of life of cancer patients undergoing radiation therapy. BioCurity Pharmaceuticals Inc., a clinical stage biopharmaceutical company with a mission to fill the unmet need of preventing radiation therapy’s sometime serious and permanent side effects, has filed with the SEC to launch a Regulation Crowdfunding Offering. The company’s crowdfunding will support development of drugs which received promising data in preclinical studies at Florida hospitals and facilities. The technology, in its topical and IV form, is projected to treat side effects for multiple cancers including breast, lung, head and neck, prostate and colorectal cancers. BioCurity’s first candidate is a topical formulation for breast cancer patients which would be used to prevent or mitigate burns, scaring and exposure of internal organs to radiation, such as the heart. 


The Business Development Board of Palm Beach County (BDB) has not only assisted BioCurity in the past with making the right local connections, but recently promoted its growth to hundreds of business leaders in the county. BioCurity will also be participating in the BDB Breakfast, where Dr. Cheryl Baker, the scientific co-founder of the company, will speak about the impact they are trying to make. Fostering the growth of local life science companies is a priority of the BDB’s economic development efforts. 


  • Over 3 Billion dollars spent annually in the US treating radiation therapy side effects
  • Approximately 6 million people a year receive radiation globally
  • FDA Initial Drug Application (IND) submission pathway with a Pre-IND meeting.
  • Considering clinical trials locally
  • Providing visibility to Palm Beach county biotechnology through online capital raises
  • New employees and senior management have relocated to Palm Beach county with the projection of adding 15 more professional, scientific and administrative staff by 2023
  • Committed to the growth of Palm Beach county by utilizing local professional services

“BioCurity believes that fighting cancer is hard enough and patients should not suffer from the medical complications of lifesaving radiation therapy,” said Dr. Cheryl Baker, Scientific Co-Founder, BioCurity

“BioCurity Pharmaceuticals is revolutionizing treatments for cancer patients. That’s an amazing technology to support cancer patients undergoing lifesaving radiation therapy using Jupiter, FL as its Launchpad,” said Kelly Smallridge, President and CEO, Business Development Board.

Notice of Funds Disbursement

11 days ago

[The following is an automated notice from the StartEngine team].


As you might know, BioCurity Pharmaceuticals Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in BioCurity Pharmaceuticals Inc. be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.


Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}